On August 26, Moderna, Inc. fell 3.37% in pre-market trading to $153.25/share, with turnover of approximately $45.54 million. The decline follows a 14.36% surge in the previous session to $158.83, driven by a Wolfe Research upgrade and continued momentum from the mRNA cancer vaccine breakthrough.

The stock remains in a volatile price-discovery phase after its historic 177% single-day surge on August 19, when Moderna and Merck announced positive Phase III results for their personalized mRNA melanoma vaccine intismeran autogene. Since then, the stock has experienced extreme swings including a 23.5% pullback, a 16% rebound, and multiple volatile sessions. While numerous Wall Street firms have raised target prices — Bank of America to $170, Piper Sandler to $167, Jefferies to $150, Barclays to $125, and Goldman Sachs to $120 — several targets remain below the current trading level, suggesting short-term overvaluation concerns. Options market implied volatility sits at the 99.6th percentile, reflecting intense bull-bear contention as investors weigh the transformative potential of mRNA oncology against near-term profit-taking pressures.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)